Biogen gamma interferon agreement
Executive Summary
Firm has finalized a licensing agreement with Baxter Travenol covering Immuneron (gamma interferon) for use in the treatment of cancer. A preliminary letter of intent between the two companies was signed in June ("The Pink Sheet" July 14, p. 4). The worldwide development and marketing agreement does not include West Germany and the Far East. Biogen retains rights to gamma interferon for noncancer indications.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.